Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world spesolimab effectiveness in acrodermatitis continua of Hallopeau
ChiCTR2500105267Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spesolimab in Acrodermatitis continua of Hallopeau (ACH), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Symptom score (GPPGA and mNPASI) and Patient-reported outcomes (PROs). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
spesolimab
03
Conditions
Acrodermatitis continua of Hallopeau (ACH)
Beyond the preview
Go deeper on ChiCTR2500105267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105267.